These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 22211481)

  • 1. Lipoprotein-associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis.
    Winkler K; Hoffmann MM; Krane V; Drechsler C; Wanner C;
    Eur J Clin Invest; 2012 Jul; 42(7):693-701. PubMed ID: 22211481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
    Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
    J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein associated phospholipase A2 concentration predicts total and cardiovascular mortality independently of established risk factors (The Ludwigshafen Risk and Cardiovascular Health Study).
    Kleber ME; Wolfert RL; De Moissl GD; Grammer TB; Dietz S; Winkelmann BR; Boehm BO; März W
    Clin Lab; 2011; 57(9-10):659-67. PubMed ID: 22029180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
    Wanner C; Krane V; März W; Olschewski M; Mann JF; Ruf G; Ritz E;
    N Engl J Med; 2005 Jul; 353(3):238-48. PubMed ID: 16034009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
    Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
    Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
    Maki KC; Bays HE; Dicklin MR; Johnson SL; Shabbout M
    J Clin Lipidol; 2011; 5(6):483-92. PubMed ID: 22108152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
    Krane V; Winkler K; Drechsler C; Lilienthal J; März W; Wanner C;
    Am J Kidney Dis; 2009 Nov; 54(5):902-11. PubMed ID: 19781835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAR VaS--Short Term Atorvastatin Regime for Vasculopathic Subjects: a randomized placebo-controlled trial evaluating perioperative atorvastatin therapy in noncardiac surgery.
    Neilipovitz DT; Bryson GL; Taljaard M
    Can J Anaesth; 2012 Jun; 59(6):527-37. PubMed ID: 22528165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationship between concentration of lipoprotein-associated secretory phospholipase A2 and markers of subclinical atherosclerotic lesion of the arterial wall in patients with low and moderate risk by SCORE scale].
    Urazalina SZh; Titov VN; Vlasik TN; Balakhonova TV; Karpov IuA; Kukharchuk VV; Boĭtsov SA
    Ter Arkh; 2011; 83(9):29-35. PubMed ID: 22145385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study.
    Wägner AM; Sánchez-Quesada JL; Benítez S; Bancells C; Ordóñez-Llanos J; Pérez A
    Diabetes Res Clin Pract; 2011 Jul; 93(1):e25-8. PubMed ID: 21440948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.
    Sever PS; Chang CL; Gupta AK; Whitehouse A; Poulter NR;
    Eur Heart J; 2011 Oct; 32(20):2525-32. PubMed ID: 21873710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The collaborative atorvastatin diabetes study: preliminary results.
    Owen OG
    Int J Clin Pract; 2005 Jan; 59(1):121-3. PubMed ID: 15707477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH;
    Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
    Gumprecht J; Gosho M; Budinski D; Hounslow N
    Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics.
    Wanner C; Krane V; März W; Olschewski M; Asmus HG; Krämer W; Kühn KW; Kütemeyer H; Mann JF; Ruf G; Ritz E;
    Kidney Blood Press Res; 2004; 27(4):259-66. PubMed ID: 15316128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial.
    Durazzo AE; Machado FS; Ikeoka DT; De Bernoche C; Monachini MC; Puech-Leão P; Caramelli B
    J Vasc Surg; 2004 May; 39(5):967-75; discussion 975-6. PubMed ID: 15111846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players.
    Pokharel Y; Nambi V; Martin SS; Hoogeveen RC; Nasir K; Khera A; Wong ND; Jones PH; Boone J; Roberts AJ; Ballantyne CM; Virani SS
    Atherosclerosis; 2014 Oct; 236(2):251-6. PubMed ID: 25105582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.